Page last updated: 2024-11-13

rb 006

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID86278324
MeSH IDM0505027

Synonyms (11)

Synonym
rb-006
rb 006
z219a1184z ,
rb006
959716-32-6
pegnivacogin sodium
pegnivacogin sodium [usan]
rb 006 sodium salt
unii-z219a1184z
rb006 sodium salt
Q27294885

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Active and safe reversibility of anticoagulation is an unmet need in clinical care."( A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
Alexander, JH; Becker, RC; Chan, MY; Harrington, RA; Rusconi, CP; Tonkens, RM, 2008
)
0.35
" There was no major bleeding and there were no other serious adverse events."( A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
Alexander, JH; Becker, RC; Chan, MY; Harrington, RA; Rusconi, CP; Tonkens, RM, 2008
)
0.35
" REG1 has not been studied in invasively managed patients with ACS nor has an optimal level of reversal allowing safe sheath removal been defined."( A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.
Aberle, LH; Alexander, JH; Becker, RC; Bode, C; Buller, CE; Cohen, MG; Cornel, JH; Delarche, N; Kasprzak, JD; Mehran, R; Montalescot, G; Natarajan, M; Povsic, TJ; Ring, ME; Rynkiewicz, A; Vavalle, JP; Zelenkofske, SL; Zeymer, U, 2013
)
0.39
"At least 50% reversal is required to allow safe sheath removal after cardiac catheterization."( A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.
Aberle, LH; Alexander, JH; Becker, RC; Bode, C; Buller, CE; Cohen, MG; Cornel, JH; Delarche, N; Kasprzak, JD; Mehran, R; Montalescot, G; Natarajan, M; Povsic, TJ; Ring, ME; Rynkiewicz, A; Vavalle, JP; Zelenkofske, SL; Zeymer, U, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" The primary objective was to determine the safety profile and to characterize the pharmacodynamic responses in this first-in-human study."( First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Aberle, LG; Alexander, JH; Becker, RC; Cannon, RO; Dyke, CK; Harrington, RA; Kleiman, NS; Lin, M; Melloni, C; Myles, SK; Rusconi, CP; Steinhubl, SR, 2006
)
0.33
" Pharmacodynamic samples were collected serially."( First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Aberle, LG; Alexander, JH; Becker, RC; Cannon, RO; Dyke, CK; Harrington, RA; Kleiman, NS; Lin, M; Melloni, C; Myles, SK; Rusconi, CP; Steinhubl, SR, 2006
)
0.33
"To test the multiple repeat-dose safety, intraindividual pharmacodynamic reproducibility and graded active reversibility of REG1."( A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
Alexander, JH; Becker, RC; Chan, MY; Harrington, RA; Rusconi, CP; Tonkens, RM, 2008
)
0.35
"This is the first human study demonstrating multiple repeat-dose safety, intraindividual pharmacodynamic reproducibility and graded active reversibility of an RNA aptamer-oligonucleotide antidote pair."( A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
Alexander, JH; Becker, RC; Chan, MY; Harrington, RA; Rusconi, CP; Tonkens, RM, 2008
)
0.35
"We performed detailed pharmacokinetic and pharmacodynamic modeling of REG1, an anticoagulation system composed of the direct factor IXa (FIXa) inhibitor pegnivacogin (RB006) and its matched active control agent anivamersen (RB007), with a focus on level of target inhibition to translate phase 1 results to phase 2 dose selection."( Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.
Alexander, JH; Becker, RC; Chan, MY; Cohen, MG; Harrington, RA; Povsic, TJ; Rusconi, CP; Wargin, WA; Zelenkofske, SL, 2011
)
0.37
" To validate dose selection and stability of anticoagulation throughout the time of cardiac catheterization at an early stage of the clinical trial, 33 patients, 22 of whom had not received recent prior heparin, underwent thorough pharmacokinetic and pharmacodynamic assessment."( Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.
Alexander, JH; Becker, RC; Bode, C; Buller, CE; Cohen, MG; Krasnow, J; Krolick, M; Mehran, R; Povsic, TJ; Rusconi, CP; Wargin, WA; Zelenkofske, SL, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" Our approach decreased the need for extensive dose-response studies, reducing the duration, complexity and cost of clinical development."( Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.
Alexander, JH; Becker, RC; Chan, MY; Cohen, MG; Harrington, RA; Povsic, TJ; Rusconi, CP; Wargin, WA; Zelenkofske, SL, 2011
)
0.37
" In this pre-specified substudy, blood samples were drawn in the presence or absence of corn trypsin inhibitor at specified times within each dosing cohort."( The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.
Alexander, JH; Becker, RC; Ortel, TL; Povsic, TJ; Rusconi, CP; Vavalle, JP; Wargin, WA; Zelenkofske, S, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (20.83)29.6817
2010's19 (79.17)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.38 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index40.78 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (28.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (50.00%)5.53%
Reviews4 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]